Clinical trial
Rifaximin, Loperamide and the Combination to Treat Travelers' Diarrhea
NCT00292344 · The University of Texas Health Science Center, Houston, Other · Completed
Key facts
| NCT number | NCT00292344 |
|---|---|
| Title | Rifaximin, Loperamide and the Combination to Treat Travelers' Diarrhea |
| Official title | Rifaximin in Standard Three-Day Dosing With and Without the Antimotility Drug, Loperamide, in the Treatment of Travelers' Diarrhea |
| Lead sponsor | The University of Texas Health Science Center, Houston, Other |
| Collaborators | Bausch Health Americas, Inc. Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Travelers' Diarrhea |
| Intervention type | Drug |
| Interventions | Rifaximin and loperamide |
| Enrollment | 316 |
| Start date | Jun 1, 2004 |
| Completion | Aug 1, 2005 |
| First posted | Feb 15, 2006 |
| Last update posted | Apr 20, 2009 |
| Countries | Mexico |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: